| Trial ID: | L3160 |
| Source ID: | NCT05990374
|
| Associated Drug: |
Duragtide, Semaglutide, Losenatide, Tirzepatide, Ebenatide, Etc
|
| Title: |
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
|
| Outcome Measures: |
Primary: Effects of different GLP-1 on blood glucose, The changes of blood glucose fluctuation after treatment, 1,2,3,4 year | Secondary: Effects of different GLP-1 on body fat mass, The changes of body fat mass after treatment, 1,2,3,4 year
|
| Sponsor/Collaborators: |
Sponsor: Nanjing First Hospital, Nanjing Medical University
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2023-08-01
|
| Completion Date: |
2024-01-01
|
| Results First Posted: |
|
| Last Update Posted: |
2023-08-14
|
| Locations: |
Nanjing First Hospital, Nanjing Medical Univesity, Nanjing, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05990374
|
